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Background: Severe pruritus is the primary symptom in 
atopic dermatitis (AD). Recently, the novel cytokine IL-31 
has been implicated in the itching associated with AD.   
Objective: We performed this study to determine whether 
IL-31 serum levels are elevated in AD patients and to better 
characterize the relationship between serum IL-31 level and 
other established laboratory parameters. Methods: We 
recruited 55 AD patients, 34 with allergic type AD and 21 
with non-allergic type AD, and 38 healthy, non-atopic 
controls. We checked the laboratory values, severity score, 
and serum IL-31 levels in all patients and controls, and IL-31 
mRNA levels in lesion skin were measured in 13 subjects 
with AD and in four controls. Results: AD patients displayed 
significantly higher levels of serum IL-31 that were 
associated with serum IgE, disease severity, and subjective 
itch intensity. In AD patients, IL-31 mRNA levels from the 
lesional skin samples also correlated with serum IL-31 level.  
Conclusion: IL-31 is likely one of the many mediators 
inducing inflammation and pruritus in AD. Although our 
limited sample size prevents us from making any definitive 
conclusions, our data demonstrate a strong correlation 
between IL-31 mRNA level and serum IL-31 protein level, 
which has never been reported before. Moreover, we found 
correlations between serum IL-31 level and serum IgE, 
eosinophil cationic protein, disease severity, and subject itch 
intensity in certain degrees in AD patients. (Ann Dermatol 
23(4) 468∼473, 2011)
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INTRODUCTION
Pruritus is arguably the most important symptom in atopic 
dermatitis (AD), as it significantly impairs patient’s quality 
of life. Accordingly, one of the main goals in AD treat-
ment is itch management, although AD-associated pruritis 
is often refractory to most traditional H1-antihistamine 
therapies. The etiology of pruritus in AD is not yet fully 
understood, however, several endogenous mediators-ne-
uropeptides, neurotransmitters, proteinases, arachidonic 
derivatives, and cytokines have been implicated in itch 
pathophysiology
1.
Recently, a novel cytokine, IL-31, was linked to the 
pathogenesis of pruritis in several chronic inflammatory 
skin diseases. IL-31 mRNA and protein expression is 
largely restricted to CD4+ T cells, particularly skin-homing 
CD45RO+ (memory) cutaneous lymphocyte-associated 
antigen-positive T cells
2 found in the peripheral blood of 
AD patients and normal controls. To exert its physiologic 
effect, IL-31 binds to a heterodimeric receptor composed 
of IL-31 receptor A and oncostatin M receptor. 
When compared with healthy controls, AD patients IL-31 and Atopic Dermatitis
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express increased IL-31 mRNA levels in both lesional and 
nonlesional skin
3. In addition to AD, IL-31 mRNA 
expression is also highly upregulated in allergic contact 
dermatitis, but not in plaque psoriasis
4. Moreover, IL-31 
expression has been associated with IL-4 and IL-13 in both 
types of pruritic eczema.
Several studies have provided further evidence suggesting 
a possible etiologic role for IL-31 in AD. IL-31 transgenic 
mice were found to express a phenotype closely mimic-
king AD
5. Specifically, the mice displayed many clinical 
hallmarks of AD but had normal serum IgE levels
5. These 
data seem to indicate that IL-31 is predominantly pro-
duced by Th2 cells, although additional amounts of the 
cytokine may be also produced by Th1 cells
5. In human 
AD patients, IL-31 mRNA was found to be elevated re-
gardless of disease severity or serum IgE
4. Conversely, the 
common haplotype of the IL-31 gene was strongly linked 
to non-atopic eczema (or non-allergic AD), indicating that 
an altered regulation of IL-31 gene expression could be 
the disease-causing factor in AD
6. Grimstad et al. used an 
AD-like murine model to demonstrate that monoclonal 
IL-31 rat-anti-mouse antibody was able to effectively re-
duce scratching behavior when administered during the 
onset of clinical skin manifestations
7.
With this in mind, IL-31 seems to be closely linked to AD 
pathophysiology and the pruritic symptoms. Here, we 
quantify serum IL-31 levels and IL-31 mRNA from lesional 
skin biopsies from AD patients and controls. Laboratory 
parameters were also examined to identify any other bio-
chemical variances associated with increases in IL-31. 
Additionally, serum IL-31 levels were compared with ob-
jective disease severity and patient-reported subjective 
itch and sleep loss to determine if increases in IL-31 corre-
lated with worsening patient symptoms. 
MATERIALS AND METHODS
Patients
Fifty-five patients (mean age: 12.64 years) with AD were 
recruited from the Samsung Medical Center between 
March 2008 and February 2009. The diagnosis of AD, the 
criteria for AD stratification into ADe (allergic or extrinsic 
type of AD) and ADi (non-allergic or intrinsic type of AD), 
and the laboratory blood tests and allergen prick tests 
were the same as in our previous study
8,9. All patients ful-
filled the Hanifin and Rajka criteria
10. Based on clinical 
history and total and specific serum IgE, all subjects with 
AD were classified as either having ADe or ADi. Patients 
with a total serum IgE level ≥200 U/ml and positive spe-
cific serum IgE antibodies toward multiple common in-
halant and food allergens were classified as having ADe. 
Conversely, individuals were classified as having ADi if 
they exhibited the clinical phenotype of AD but lacked 
any history of other atopic disease, had total serum IgE 
levels within the normal range, and did not exhibit any 
detectable specific serum IgE response. In total, 34 sub-
jects with ADe, 21 subjects with ADi, and 38 non-atopic 
controls (mean age 22.8±2.5 years) were included in the 
study. 
This study was conducted according to the Declaration of 
Helsinki Principles, and written informed consent was ob-
tained from all participants. The Samsung Medical Centre 
Ethics Committee approved this study.
Clinical and laboratory measurement
AD severity was calculated using the SCORAD index
11, 
and eosinophil count, serum eosinophil cationic protein 
(ECP), total serum IgE, and specific serum IgE response to 
a panel of food allergens and aeroallergens were meas-
ured using a CAP System (Pharmacia, Uppsala, Sweden). 
Subjective itch and sleep loss intensity were measured us-
ing a patient-reported 0∼10 scale (0: no pruritus/sleep 
loss at all, 10: severe pruritus/sleep loss during the last 
three nights).
Protein assay using ELISA
Serum IL-31 protein levels were measured using ELISA 
with the DuoSet human IL-31 ELISA Development kit 
(Human IL-31 DuoSet; R&D Systems; Minneapolis, MN, 
USA). All analyses were performed according to the man-
ufacturer’s protocol.
RNA extraction
Punch biopsies from lesional skin of patients with ADe 
(n=8) and ADi (n=5) were collected for mRNA analysis. 
Similar biopsies were also collected from control in-
dividuals without any history of atopic disease (n=4). 
Isolation of total RNA from human skin biopsy was per-
formed using an easy-BLUE
TM Total RNA Extraction Kit 
(Intron, Seoul, Korea).
Reverse transcriptase polymerase chain reaction (RT- 
PCR)
cDNA synthesis was performed using the M-MLV RT kit 
(Intron) according to the manufacturer's instructions. The 
primer sequences for the target genes were designed using 
the GENBANK accession sequences with the Primer 3 
program (http://frodo.wi.mit.edu/). The forward and reverse 
primers for IL-31 were 5'-TCGAGGAATTACAGTCCC-
TCTC-3' and 5'-TGTCGAGGTGCTCTATGATCTC-3', res-
pectively. Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was used for quantification of the control speci-S Kim, et al
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Fig. 1. IL-31 serum levels in patients with extrinsic and intrinsic
types of AD versus those of non-atopic controls. AD: atopic 
dermatitis, ADe: allergic or extrinsic type of AD, ADi: 
non-allergic or intrinsic type of AD.
Fig. 2. (A) RT-PCR analysis of IL-31 expression using RNA extracted from skin biopsies. This analysis showed an increase in IL-13 
mRNA in some atopic patients (1∼13). (B) The band intensity was quantified with ImageJ software (NIH), and the percentages were
the ratio of optical intensity normalized to the GAPDH signal. The level of IL-31 mRNA in the controls (N1∼N4) was undetectable.
(C) The IL-31 protein level in the serum from the patients in the RT-PCR experiment. Patients 1∼4, 9∼12 are ADe and patients
5∼8, and 13 are ADi. (D) Boxplot of IL-31/GAPDH mRNA(%) in pruritus score 0∼4 and 5∼10 levels. RT-PCR: reverse trascriptase
polymerase chain reaction, GAPDH: glyceraldehyde-3-phosphate dehydrogenase, ADe: allergic or extrinsic type of AD, ADi: non-allergic
or intrinsic type of AD.
mens. The reaction mixture for each gene PCR contained 
1μl aliquot from the RT reaction, 1μl of each primer, and 
17μl of i-Master mix PCR solution (Intron), producing a 
final reaction volume of 20μl. The amplification products 
were resolved in 1.5% agarose gel with ethidium bromide. 
To quantitate the PCR products, the gels were scanned and 
the pixel intensity for each band was assessed using the 
ImageJ program (NIH Image). All results were subsequently 
normalized to account for the amount of GAPDH present.
Statistical analyses
All statistical analyses were performed with the statistical 
software package SigmaStat for Windows (Jandel Scientific 
Erkrath, Wiesbaden, Germany). To test statistical sig-
nificance, the data were analyzed with the nonparametric 
method, as our results did not display a normal distri-
bution. To compare the characteristics of the subgroups, 
the Wilcoxon two-sample test was employed. Correla-IL-31 and Atopic Dermatitis
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Table 1. Correlation between serum IL-31 protein level and IL-31
mRNA level in atopic dermatitis patients versus those of the 
controls
Spearman’s 
correlation Kendall’s tau Pearson’s 
correlation
      r 0.5471 0.4189 0.5749
   p-value 0.0141 0.0206 0.0099
tions between serum IL-31 level and laboratory parame-
ters were assessed using Pearson’s correlation. To assess 
for correlation between serum IL-31 and IL-31 mRNA, 
Spearman’ rank correlation, Kendall’s tau coefficient, and 
Pearson’s correlation were used. In all cases, p＜0.05 was 
defined as statistically significant.
RESULTS
IL-31 serum levels are significantly higher in AD 
patients 
Mean serum IL-31 level was significantly elevated (p＜0.05) 
in AD patients (43,142.8±66,981.6 pg/ml) compared to 
those of the normal controls (7,881.8±1,842.7 pg/ml). In 
AD subtypes, serum IL-31 levels were still significantly 
higher (p＜0.05) in both ADe (44,757±68,436.3 pg/ml) 
and ADi (40,529.45±66,138 pg/ml) groups compared to 
those of the healthy controls. Interestingly, no statistically 
significant difference in serum IL-31 levels was found 
between subgroups (Fig. 1). Therefore, IL-31 may possibly 
be valuable for the diagnosis of AD. 
Serum IL-31 level is correlated with total serum IgE and 
ECP
In AD patients, the mean total serum IgE, ECP, and 
eosinophil count were 1,079.3±1,511.4 U/ml, 32.21±29.0 
ng/ml, and 432.9±344.8/ul, respectively. The relationship 
between serum total IgE (p-value; 0.041), ECP (p-value; 
0.04) and serum IL-31 level was the only marginally 
statistically significant association.
Serum IL-31 level is correlated with SCORAD index 
and subjective itch intensity 
In AD patients, the mean SCORAD index, subjective 
pruritus intensity, and sleep loss were 40.4±13.8, 5.7±2.0, 
and 4.44±2.1, respectively. The serum IL-31 level was 
statistically correlated with SCORAD index (p-value; 
0.003) and subjective itch intensity (p-value; 0.03) in AD 
patients, however, there was no correlation between 
serum IL-31 levels and sleep loss (p-value; 0.13). 
Serum IL-31 level is significantly correlated with 
cutaneous IL-31 mRNA
Skin biopsies from AD patients (8 ADe and 5 ADi) and 
controls (n=4) were analyzed for IL-31 mRNA using 
RT-PCR. Punch biopsies were obtained from lesional skin 
of patients with AD and normal skin from controls and 
were compared with the previously obtained serum IL-31 
levels using ELISA (Fig. 2A). IL-31 transcripts were 
detected in AD patients but not in normal groups. The 
mean ratio of IL-31/GAPDH mRNA band intensity in AD 
patients was clearly higher than that in the controls (Fig. 
2B). The IL-31 mRNA levels in biopsies from AD patients 
were consistent with serum IL-31 levels (Fig. 2C). These 
data confirm that, among AD patients, the levels of IL-31 
protein and IL-31 mRNA increased correspondingly, and, 
when compared with normal subjects, this difference was 
statistically significant and useful for the diagnosis of AD 
patients (Table 1, p=0.0141 and 0.0206, respectively, 
using Spearman's correlation and Kendall's tau). In 
addition, there was statistical significance to alternative 
hypothesis that mean of IL31-mRNA in pruritus score 5∼
10 is greater than that in pruritus score 0∼4 via two 
sample t-test (Fig. 2D, p=0.0077). This result is supportive 
to other conclusions that serum IL-31 level is positively 
correlated with subjective itch intensity and IL-31 mRNA 
level.
DISCUSSION
AD is a highly pruritic inflammatory skin disease that is 
believed to alter the intrinsic immunologic response of 
those afflicted. Acute AD skin lesions are characterized by 
a predominant infiltration of CD45RO+ activated memory 
T cells and increased local expression of Th2 type 
cytokines, especially IL-4 and IL-13, and chemokines
12,13. 
Pruritus is defined as a sensation leading to the desire to 
scratch. Both central and peripheral mediators are im-
portant in the etiology of pruritus. Specifically, histamine, 
proteinase, substance P, neurotrophin, prostanoids, and in-
terleukins are all compounds believed to play a role in pe-
ripherally mediated pruritis
14. Emerging research suggests 
that many additional intrinsic biochemical compounds 
may also contribute to pruritis in AD patients. Most nota-
bly, IL-2 is known to produce itching in individuals with 
AD as well as cancer patients receiving exogenous re-
combinant IL-2
15. Immunomodulators like tacrolimus and 
pimecrolimus seem to inhibit the production of IL-2 and 
are thus very effective in treating AD. Lee et al.
16 im-
plicates transepidermal water loss, serum IgE, and β-en-
dorphin as important and independent biologic markers 
involved in the development of itch intensity in AD.S Kim, et al
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Although IL-31 transgenic mice exhibit clinical features 
similar to AD, they did not express the increased serum 
levels of IgE
5 seen in IL-4 transgenic mice
17. Accordingly, 
IL-31 seems to have a different pathophysiologic mecha-
nism than IL-4 in the etiology of AD. Notably, skin levels 
of IL-31 mRNA were found to be higher in NC/Nga mice 
with scratching behavior than in similar mice without 
scratching behavior. These results imply that IL-31 ex-
pression may precede the appearance of dermatitis, and 
that IL-31-induced excessive scratching may play an 
important role in the early stages of dermatitis in mice
18.
We show serum IL-31 levels to be elevated in AD patients 
regardless of AD subtype. Moreover, our data indicate 
that, in AD patients, serum IL-31 levels are marginally 
associated with serum IgE level, ECP, disease severity, and 
subjective itch intensity. In previous study, Raap et al.
19 
found that serum IL-31 levels were significantly higher in 
both ADe and ADi patients, without any difference 
between AD subgroups, and also showed that SCORAD 
score was significantly correlated with serum IL-31 level 
in all AD patients. On the other hands, Neis et al.
4 
reported no correlations between IL-31 mRNA level and 
either disease severity or serum IgE level in AD patients as 
the IL-31 transgenic mice showed intrinsic type of AD. 
These findings suggest an association between itching and 
IL-31 level and imply that such itching could induce the 
sleep loss that was observed in our experiment.  
We also found that the IL-31 mRNA levels in skin biopsies 
from AD patients were higher than those from controls 
(undetectable in our experiments), and demonstrated 
significant correlations between IL-31 mRNA and serum 
IL-31 level in AD patients, and also demonstrated 
significant correlations between IL-31 mRNA and pruritus 
score in AD patients. Previously, IL-31 mRNA levels were 
quantified in both lesional and nonlesional skin biopsies 
from AD patients and other skin diseases
2-4. Data 
regarding serum IL-31 levels in AD patients has also been 
reported
19. However, there has been no report to date 
correlating IL-31 mRNA levels with serum IL-31 protein 
levels in humans.
In conclusion, our results suggest that IL-31 is one of the 
mediators inducing inflammation and pruritus in AD. 
Although our limited sample size prevents us from making 
any definitive conclusions, we demonstrate a strong cor-
relation between IL-31 mRNA level and serum IL-31 
protein level, which was never reported before. Moreover, 
we found correlations between serum IL-31 level and 
serum IgE, ECP, disease severity and subject itch intensity 
in certain degrees in AD patients. To better elucidate these 
relationships, further studies are warranted for a better 
understanding of the complex etiology of AD-associated 
pruritus. 
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